Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

FDA Approval of E7777 (Denileukin Diftitox) for R/R CTCL - Summary o…

Yale Cancer Center

F. Foss

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith